Inhibition of heat shock protein 90 in the mouse spinal cord enhances opioid antinociception via the upregulation of dual specificity protein phosphatase 15 (DUSP15) in CGRP neurons
- 1Department of Pharmacology, College of Medicine, University of Arizona
- 2Comprehensive Center for Pain and Addiction, University of Arizona
Abstract
In an extended series of studies, we have shown that Heat shock protein 90 (Hsp90) has a novel role in regulating opioid signal transduction and antinociception in both the brain and spinal cord. Inhibition in the spinal cord enhances opioid antinociception, which led to the finding that an isoform-selective Hsp90 inhibitor could improve opioid therapy, both enhancing pain relief and reducing side effects. However, the signaling mechanisms for this activity are still not fully understood. We thus identified Dual Specificity Phosphatase 15 (DUSP15) from an earlier proteomic study as a protein enhanced in the spinal cord after Hsp90 inhibition. Using male and female CD-1 mice, we confirmed that DUSP15 is upregulated in the dorsal horn of the spinal cord after Hsp90 inhibitor (17-AAG) treatment. Using CRISPR and siRNA-mediated knockdown, we showed that DUSP15 was necessary for the enhanced morphine antinociception after Hsp90 inhibitor treatment in both the tail flick and post-surgical paw incision pain models. Using immunohistochemistry (IHC) and behavioral tools, we placed DUSP15 upstream of both ERK MAPK and AMPK in the opioid signaling cascade. We then used IHC to demonstrate that DUSP15 upregulation occurs at least in part in CGRP neurons, and using cell-selective CRISPR, showed that DUSP15 in CGRP neurons is necessary for the enhanced antinociception observed with spinal Hsp90 inhibitor treatment. Together these studies further expand the known mechanisms by which Hsp90 regulates opioid signal transduction and pain relief and provide basic science insight into a potential strategy to improve opioid therapy using Hsp90 inhibitors.
Related
- c-MET Inhibition Is Accompanied by PD-L1 Upregulation and Immunosuppression-Related Tumor Microenvironment Changes in Esophageal Squamous Cell Carcinoma, With Enhanced Antitumor Activity in Combination With Anti-PD-1 Therapy.
- MicroRNA-155-5p-dependent upregulation of PDCD4 is involved in oridonin-induced proliferation inhibition of leukemia cells
- ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells
- 601 GARP–TGF-β1 blockade with livmoniplimab reprograms spatial tumor niches and enhances PD-1 inhibition in human tumor explants
- FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models.
BibTeX
@article{gabriel2026inhibition,
title = {{Inhibition of heat shock protein 90 in the mouse spinal cord enhances opioid antinociception via the upregulation of dual specificity protein phosphatase 15 (DUSP15) in CGRP neurons}},
author = {Katherin A. Gabriel and Jessica L. Bowden and John M. Streicher},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1734504},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1734504/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Inhibition of heat shock protein 90 in the mouse spinal cord enhances opioid antinociception via the upregulation of dual specificity protein phosphatase 15 (DUSP15) in CGRP neurons
AU - Katherin A. Gabriel
AU - Jessica L. Bowden
AU - John M. Streicher
PY - 2026
DA - 2026/10/19
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1734504
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1734504/full
AB - In an extended series of studies, we have shown that Heat shock protein 90 (Hsp90) has a novel role in regulating opioid signal transduction and antinociception in both the brain and spinal cord. Inhibition in the spinal cord enhances opioid antinociception, which led to the finding that an isoform-selective Hsp90 inhibitor could improve opioid therapy, both enhancing pain relief and reducing side effects. However, the signaling mechanisms for this activity are still not fully understood. We thus identified Dual Specificity Phosphatase 15 (DUSP15) from an earlier proteomic study as a protein enhanced in the spinal cord after Hsp90 inhibition. Using male and female CD-1 mice, we confirmed that DUSP15 is upregulated in the dorsal horn of the spinal cord after Hsp90 inhibitor (17-AAG) treatment. Using CRISPR and siRNA-mediated knockdown, we showed that DUSP15 was necessary for the enhanced morphine antinociception after Hsp90 inhibitor treatment in both the tail flick and post-surgical paw incision pain models. Using immunohistochemistry (IHC) and behavioral tools, we placed DUSP15 upstream of both ERK MAPK and AMPK in the opioid signaling cascade. We then used IHC to demonstrate that DUSP15 upregulation occurs at least in part in CGRP neurons, and using cell-selective CRISPR, showed that DUSP15 in CGRP neurons is necessary for the enhanced antinociception observed with spinal Hsp90 inhibitor treatment. Together these studies further expand the known mechanisms by which Hsp90 regulates opioid signal transduction and pain relief and provide basic science insight into a potential strategy to improve opioid therapy using Hsp90 inhibitors.
SN - 1663-9812
ER -